PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.66%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-4.38%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-15.27%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-23.77%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-15.66%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-15.66%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-15.66%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.19%
10Y revenue/share CAGR above 1.5x 3088.T's 38.75%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
66.93%
5Y revenue/share CAGR above 1.5x 3088.T's 18.88%. David Dodd would look for consistent product or market expansions fueling outperformance.
36.33%
3Y revenue/share CAGR above 1.5x 3088.T's 6.54%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
197.70%
Similar net income/share CAGR to 3088.T's 206.13%. Walter Schloss would see parallel tailwinds or expansions for both firms.
61.57%
5Y net income/share CAGR at 75-90% of 3088.T's 80.90%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
48.90%
3Y net income/share CAGR 1.25-1.5x 3088.T's 38.41%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
222.31%
Equity/share CAGR of 222.31% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
133.90%
5Y equity/share CAGR above 1.5x 3088.T's 51.40%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
65.83%
3Y equity/share CAGR above 1.5x 3088.T's 32.98%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
-10.00%
Negative 5Y dividend/share CAGR while 3088.T stands at 100.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
50.00%
3Y dividend/share CAGR similar to 3088.T's 50.00%. Walter Schloss finds parallel short-term dividend strategies for both companies.
147.76%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
8.38%
Inventory growth well above 3088.T's 1.82%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.02%
Asset growth well under 50% of 3088.T's 3.62%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.65%
Similar to 3088.T's 3.52%. Walter Schloss finds parallel capital usage or profit distribution strategies.
-7.61%
We’re deleveraging while 3088.T stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
1.36%
SG&A growth well above 3088.T's 2.41%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.